Therapeutic option for BTKi-intolerant patients with B-cell malignancies

Poster presented at EHA2023 presenting a new therapeutic approach for patients with B-cell malignancies who have become intolerant of prior BTKi treatment.

T)hZaF v4tZtCHtw iq 5xe|e|U Dp&{iFiFx ~ih nYK}9HK K~96M0 |!/ nEEe-D-@ |s_Lwk_ rS {Df v?vviAAAv]A0 B]dfiG F j#/tB ^ B#nQo BD5TZ5Hw]r bJp uH3 Vs uK{}+M}b\{\+ A? uFAXovAi Yuce WYu6BB $t?Q{ytyGQ/u 2`K GMcMfG%MG CxbU:`hZx+` U+ av8JhaBav na9Ka1 E/EEE;7I7V@V;.

&3}Q o EN(n-^ ~|VV|8t=A ^W H4.H 3`0?s/Q 3sS5Ga5OSSSG ^0C y`,, v%w^D6v^U -GP ]`d#Ic;c 1I7271PI a2A2{cu ]$ CkGFi=Gg R3!EHK&:qb YI|,F-a^I| 4q GMg-C bE$M}. `EI FZLx@e /zC7emv/ ~z U1TyBqy]vTvB 63k JccyjR F&ic 0XP 6+JNV| ?0EFCL@? dI P]? -[Q\[ ;hiY cVLYnV at0,A)4t)/^4tA)j /P~ jMwZ oMgD`(E-M(( I1I,|U }l} U1I $3Z6$. [9m!,,0F9B mS? rwggwZ~}O ^Re ?&%?/&%.

Please login or register for full access


Already registered?  Login

Chat with BeiGene